Symbols / CYTK
CYTK Chart
About
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.61B |
| Enterprise Value | 8.09B | Income | -784.96M | Sales | 88.04M |
| Book/sh | -5.49 | Cash/sh | 7.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -13.37 | PEG | — |
| P/S | 86.46 | P/B | -11.34 | P/C | — |
| EV/EBITDA | -13.43 | EV/Sales | 91.92 | Quick Ratio | 4.36 |
| Current Ratio | 4.53 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -6.30 | EPS next Y | -4.66 | EPS Growth | — |
| Revenue Growth | 4.90% | Earnings | 2026-05-06 | ROA | -27.08% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -10.05% | Profit Margin | 0.00% | Shs Outstand | 122.26M |
| Shs Float | 119.53M | Short Float | 15.66% | Short Ratio | 9.01 |
| Short Interest | — | 52W High | 70.98 | 52W Low | 29.31 |
| Beta | 0.55 | Avg Volume | 1.90M | Volume | 338.61K |
| Target Price | $91.17 | Recom | Buy | Prev Close | $62.63 |
| Price | $62.26 | Change | -0.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$91.17
Mean price target
2. Current target
$62.26
Latest analyst target
3. DCF / Fair value
$91.17
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$62.26
Low
$61.00
High
$136.00
Mean
$91.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | main | Leerink Partners | Outperform → Outperform | $84 |
| 2026-02-25 | main | Citizens | Market Outperform → Market Outperform | $96 |
| 2026-02-25 | main | Needham | Buy → Buy | $85 |
| 2026-02-20 | main | RBC Capital | Outperform → Outperform | $101 |
| 2026-02-03 | main | Truist Securities | Buy → Buy | $92 |
| 2026-01-21 | main | B. Riley Securities | Buy → Buy | $108 |
| 2026-01-21 | reit | RBC Capital | Outperform → Outperform | $95 |
| 2026-01-20 | main | JP Morgan | Overweight → Overweight | $74 |
| 2025-12-23 | main | Morgan Stanley | Overweight → Overweight | $71 |
| 2025-12-22 | main | RBC Capital | Outperform → Outperform | $95 |
| 2025-12-22 | main | Barclays | Overweight → Overweight | $87 |
| 2025-12-22 | main | Citizens | Market Outperform → Market Outperform | $88 |
| 2025-12-22 | main | Needham | Buy → Buy | $84 |
| 2025-12-22 | main | HC Wainwright & Co. | Buy → Buy | $136 |
| 2025-12-19 | up | Goldman Sachs | Neutral → Buy | $95 |
| 2025-12-12 | reit | Needham | Buy → Buy | $72 |
| 2025-11-11 | main | RBC Capital | Outperform → Outperform | $87 |
| 2025-11-10 | reit | B. Riley Securities | Buy → Buy | $90 |
| 2025-10-06 | main | Barclays | Overweight → Overweight | $82 |
| 2025-10-02 | main | B of A Securities | Neutral → Neutral | $56 |
- Cytokinetics Stock Slides 10% After Q4 Loss Widens: How MYQORZO’s Launch Shape the Outlook - TIKR.com Fri, 27 Feb 2026 01
- Why Cytokinetics (CYTK) Is a Buy - The Villanovan Wed, 25 Feb 2026 13
- $CYTK stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Wed, 25 Feb 2026 19
- Cytokinetics (CYTK) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Wed, 25 Feb 2026 00
- Cytokinetics (NASDAQ:CYTK) Stock Price Down 7.7% After Earnings Miss - MarketBeat Wed, 25 Feb 2026 15
- Cytokinetics (CYTK): Leerink Partners Raises Price Target | CYTK Stock News - GuruFocus hu, 26 Feb 2026 20
- Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Powerhouse with 33% Potential Upside - DirectorsTalk Interviews Mon, 23 Feb 2026 20
- Is It Too Late To Reassess Cytokinetics (CYTK) After Its 41% One Year Gain? - simplywall.st Mon, 23 Feb 2026 21
- CYTK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Mon, 23 Feb 2026 20
- Notable Wednesday Option Activity: CYTK, MDB, WBD - Nasdaq Wed, 25 Feb 2026 20
- CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Yahoo Finance Wed, 25 Feb 2026 18
- Cytokinetics (CYTK): Analyst Jason Butler Raises Price Target to $96 | CYTK Stock News - GuruFocus Wed, 25 Feb 2026 13
- Cytokinetics (NASDAQ:CYTK) Given New $84.00 Price Target at Leerink Partners - MarketBeat hu, 26 Feb 2026 20
- Cytokinetics (CYTK) Quarterly Loss Of US$183 Million Reinforces Bearish Profitability Concerns - simplywall.st hu, 26 Feb 2026 00
- CYTK Sees Positive Analyst Ratings as Needham Raises Price Target | CYTK Stock News - GuruFocus Wed, 25 Feb 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 15000 | 348900 | — | Conversion of Exercise of derivative security at price 23.26 per share. | CALLOS ANDREW | Officer | — | 2026-02-05 00:00:00 | D |
| 1 | 15000 | 928950 | — | Sale at price 61.93 per share. | CALLOS ANDREW | Officer | — | 2026-02-05 00:00:00 | D |
| 2 | 886 | 33340 | — | Conversion of Exercise of derivative security at price 37.63 per share. | CALLOS ANDREW | Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 886 | 55021 | — | Sale at price 62.10 per share. | CALLOS ANDREW | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 98 | 6217 | — | Stock Award(Grant) at price 63.44 per share. | WYSENSKI NANCY J | Director | — | 2026-01-15 00:00:00 | D |
| 5 | 197 | 12498 | — | Stock Award(Grant) at price 63.44 per share. | HARRINGTON ROBERT ARTHUR | Director | — | 2026-01-15 00:00:00 | D |
| 6 | 98 | 6217 | — | Stock Award(Grant) at price 63.44 per share. | WIERENGA WENDELL | Director | — | 2026-01-15 00:00:00 | D |
| 7 | 334 | 21189 | — | Stock Award(Grant) at price 63.44 per share. | HENDERSON JOHN TANNAHILL | Director | — | 2026-01-15 00:00:00 | D |
| 8 | 197 | 12498 | — | Stock Award(Grant) at price 63.44 per share. | KAYE EDWARD M | Director | — | 2026-01-15 00:00:00 | D |
| 9 | 197 | 12498 | — | Stock Award(Grant) at price 63.44 per share. | DALY JAMES M. | Director | — | 2026-01-15 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -494.78M | -456.68M | -307.05M | -183.71M |
| TotalUnusualItems | 1.30M | 0.00 | -24.94M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 1.30M | 0.00 | -24.94M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -589.53M | -526.24M | -388.95M | -215.31M |
| ReconciledDepreciation | 9.53M | 11.89M | 5.81M | 2.28M |
| ReconciledCostOfRevenue | 339.41M | 330.12M | 240.81M | 159.94M |
| EBITDA | -493.48M | -456.68M | -331.99M | -183.71M |
| EBIT | -503.01M | -468.58M | -337.80M | -185.98M |
| NetInterestIncome | -34.98M | -30.04M | -39.81M | -29.00M |
| InterestExpense | 86.51M | 57.67M | 51.16M | 29.33M |
| InterestIncome | 51.53M | 27.63M | 11.34M | 331.00K |
| NormalizedIncome | -590.83M | -526.24M | -364.02M | -215.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -589.53M | -526.24M | -388.95M | -215.31M |
| TotalExpenses | 554.72M | 503.74M | 418.79M | 256.74M |
| TotalOperatingIncomeAsReported | -536.25M | -496.20M | -324.20M | -186.31M |
| DilutedAverageShares | 111.98M | 96.52M | 89.83M | 76.89M |
| BasicAverageShares | 111.98M | 96.52M | 89.83M | 76.89M |
| DilutedEPS | -5.26 | -5.45 | -4.33 | -2.80 |
| BasicEPS | -5.26 | -5.45 | -4.33 | -2.80 |
| DilutedNIAvailtoComStockholders | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncomeCommonStockholders | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncome | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncomeIncludingNoncontrollingInterests | -589.53M | -526.24M | -388.95M | -215.31M |
| NetIncomeContinuousOperations | -589.53M | -526.24M | -388.95M | -215.31M |
| PretaxIncome | -589.53M | -526.24M | -388.95M | -215.31M |
| OtherIncomeExpense | -18.30M | -24.94M | ||
| OtherNonOperatingIncomeExpenses | -19.60M | |||
| SpecialIncomeCharges | 0.00 | 0.00 | -24.94M | 0.00 |
| OtherSpecialCharges | 24.94M | |||
| GainOnSaleOfSecurity | 1.30M | |||
| NetNonOperatingInterestIncomeExpense | -34.98M | -30.04M | -39.81M | -29.00M |
| InterestExpenseNonOperating | 86.51M | 57.67M | 51.16M | 29.33M |
| InterestIncomeNonOperating | 51.53M | 27.63M | 11.34M | 331.00K |
| OperatingIncome | -536.25M | -496.20M | -324.20M | -186.31M |
| OperatingExpense | 215.31M | 173.61M | 177.98M | 96.80M |
| ResearchAndDevelopment | 159.94M | |||
| SellingGeneralAndAdministration | 215.31M | 173.61M | 177.98M | 96.80M |
| GeneralAndAdministrativeExpense | 215.31M | 173.61M | 177.98M | 96.80M |
| OtherGandA | 215.31M | 173.61M | 177.98M | 96.80M |
| GrossProfit | -320.93M | -322.59M | -146.22M | -89.51M |
| CostOfRevenue | 339.41M | 330.12M | 240.81M | 159.94M |
| TotalRevenue | 18.47M | 7.53M | 94.59M | 70.43M |
| OperatingRevenue | 18.47M | 7.53M | 94.59M | 70.43M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 118.21M | 101.64M | 94.83M | 84.80M |
| ShareIssued | 118.21M | 101.64M | 94.83M | 84.80M |
| NetDebt | 562.26M | 504.43M | 544.99M | 30.17M |
| TotalDebt | 788.68M | 755.77M | 750.30M | 269.93M |
| TangibleBookValue | -135.37M | -386.32M | -107.90M | 243.86M |
| InvestedCapital | 521.75M | 231.13M | 502.68M | 386.70M |
| WorkingCapital | 928.27M | 525.37M | 710.57M | 463.81M |
| NetTangibleAssets | -135.37M | -386.32M | -107.90M | 243.86M |
| CapitalLeaseObligations | 131.56M | 138.32M | 139.72M | 127.09M |
| CommonStockEquity | -135.37M | -386.32M | -107.90M | 243.86M |
| TotalCapitalization | 510.23M | 221.05M | 501.72M | 386.70M |
| TotalEquityGrossMinorityInterest | -135.37M | -386.32M | -107.90M | 243.86M |
| StockholdersEquity | -135.37M | -386.32M | -107.90M | 243.86M |
| GainsLossesNotAffectingRetainedEarnings | 2.40M | -10.00K | -3.59M | -869.00K |
| OtherEquityAdjustments | 2.40M | -10.00K | -3.59M | -869.00K |
| RetainedEarnings | -2.70B | -2.11B | -1.59B | -1.21B |
| AdditionalPaidInCapital | 2.56B | 1.73B | 1.48B | 1.45B |
| CapitalStock | 118.00K | 102.00K | 94.00K | 84.00K |
| CommonStock | 118.00K | 102.00K | 94.00K | 84.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.54B | 1.21B | 1.12B | 597.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.36B | 1.11B | 1.04B | 525.60M |
| OtherNonCurrentLiabilities | 599.19M | 380.16M | 301.55M | 183.53M |
| NonCurrentDeferredLiabilities | 0.00 | 87.00M | ||
| NonCurrentDeferredRevenue | 0.00 | 87.00M | ||
| LongTermDebtAndCapitalLeaseObligation | 758.18M | 727.80M | 736.51M | 255.07M |
| LongTermCapitalLeaseObligation | 112.58M | 120.43M | 126.89M | 112.23M |
| LongTermDebt | 645.60M | 607.37M | 609.62M | 142.84M |
| CurrentLiabilities | 179.67M | 102.68M | 84.62M | 71.86M |
| OtherCurrentLiabilities | 21.11M | 10.56M | 1.12M | 1.54M |
| CurrentDeferredLiabilities | 52.37M | 0.00 | ||
| CurrentDeferredRevenue | 52.37M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 30.50M | 27.97M | 13.79M | 14.86M |
| CurrentCapitalLeaseObligation | 18.98M | 17.89M | 12.83M | 14.86M |
| CurrentDebt | 11.52M | 10.08M | 958.00K | |
| OtherCurrentBorrowings | 11.52M | 10.08M | 958.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 35.13M | 29.25M | 21.77M | 14.93M |
| PayablesAndAccruedExpenses | 40.56M | 34.89M | 47.94M | 40.53M |
| CurrentAccruedExpenses | 20.19M | 13.39M | 22.33M | 19.44M |
| Payables | 20.37M | 21.51M | 25.61M | 21.09M |
| AccountsPayable | 20.37M | 21.51M | 25.61M | 21.09M |
| TotalAssets | 1.40B | 824.32M | 1.01B | 841.32M |
| TotalNonCurrentAssets | 293.73M | 196.26M | 219.59M | 305.65M |
| OtherNonCurrentAssets | 7.71M | 8.00M | 9.69M | 7.19M |
| InvestmentsAndAdvances | 145.06M | 40.53M | 46.71M | 152.05M |
| InvestmentinFinancialAssets | 145.06M | 40.53M | 46.71M | 152.05M |
| AvailableForSaleSecurities | 145.06M | 40.53M | 46.71M | 152.05M |
| NetPPE | 140.97M | 147.74M | 163.19M | 146.41M |
| AccumulatedDepreciation | -37.18M | -28.35M | -17.09M | -16.19M |
| GrossPPE | 178.15M | 176.08M | 180.28M | 162.60M |
| Leases | 66.87M | 66.87M | 65.91M | 60.34M |
| ConstructionInProgress | 4.07M | 220.00K | 741.00K | 224.00K |
| OtherProperties | 97.79M | 99.67M | 103.67M | 93.38M |
| MachineryFurnitureEquipment | 9.42M | 9.32M | 9.96M | 8.65M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.11B | 628.05M | 795.19M | 535.67M |
| OtherCurrentAssets | 15.28M | 11.94M | 12.46M | 12.21M |
| PrepaidAssets | 12.21M | |||
| Receivables | 16.65M | 1.28M | 147.00K | 51.82M |
| AccountsReceivable | 16.65M | 1.28M | 147.00K | 51.82M |
| CashCashEquivalentsAndShortTermInvestments | 1.08B | 614.82M | 782.58M | 471.64M |
| OtherShortTermInvestments | 981.16M | 501.80M | 717.00M | 358.97M |
| CashAndCashEquivalents | 94.86M | 113.02M | 65.58M | 112.67M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -399.80M | -415.75M | -310.85M | -191.39M |
| RepaymentOfDebt | -9.62M | -858.00K | -188.93M | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 523.59M | 0.00 |
| IssuanceOfCapitalStock | 706.84M | 164.23M | 0.00 | 312.05M |
| CapitalExpenditure | -3.91M | -1.42M | -11.34M | -48.87M |
| InterestPaidSupplementalData | 25.97M | 10.29M | 15.16M | 9.18M |
| EndCashPosition | 95.23M | 113.40M | 67.18M | 112.67M |
| BeginningCashPosition | 113.40M | 67.18M | 112.67M | 82.98M |
| EffectOfExchangeRateChanges | 209.00K | -20.00K | 0.00 | 0.00 |
| ChangesInCash | -18.38M | 46.24M | -45.48M | 29.68M |
| FinancingCashFlow | 930.61M | 221.32M | 516.17M | 319.98M |
| CashFlowFromContinuingFinancingActivities | 930.61M | 221.32M | 516.17M | 319.98M |
| NetOtherFinancingCharges | 180.37M | 39.48M | 163.96M | -4.45M |
| ProceedsFromStockOptionExercised | 53.02M | 18.46M | 17.54M | 12.38M |
| NetCommonStockIssuance | 706.84M | 164.23M | 0.00 | 312.05M |
| CommonStockIssuance | 706.84M | 164.23M | 0.00 | 312.05M |
| NetIssuancePaymentsOfDebt | -9.62M | -858.00K | 334.66M | 0.00 |
| NetLongTermDebtIssuance | -9.62M | -858.00K | 334.66M | 0.00 |
| LongTermDebtPayments | -9.62M | -858.00K | -188.93M | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 523.59M | 0.00 |
| InvestingCashFlow | -553.10M | 239.25M | -262.13M | -147.78M |
| CashFlowFromContinuingInvestingActivities | -553.10M | 239.25M | -262.13M | -147.78M |
| NetInvestmentPurchaseAndSale | -549.19M | 240.67M | -250.80M | -98.91M |
| SaleOfInvestment | 744.23M | 875.88M | 604.59M | 426.14M |
| PurchaseOfInvestment | -1.29B | -635.21M | -855.39M | -525.04M |
| NetPPEPurchaseAndSale | -3.91M | -1.42M | -11.34M | -48.87M |
| PurchaseOfPPE | -3.91M | -1.42M | -11.34M | -48.87M |
| OperatingCashFlow | -395.89M | -414.33M | -299.52M | -142.52M |
| CashFlowFromContinuingOperatingActivities | -395.89M | -414.33M | -299.52M | -142.52M |
| ChangeInWorkingCapital | 35.66M | 3.09M | -24.70M | 8.46M |
| ChangeInOtherWorkingCapital | 52.37M | -87.00M | ||
| ChangeInOtherCurrentLiabilities | -8.60M | -10.99M | -2.33M | 47.12M |
| ChangeInPayablesAndAccruedExpense | 9.70M | 13.62M | 15.37M | 16.11M |
| ChangeInAccruedExpense | 14.18M | 17.10M | 10.84M | 15.06M |
| ChangeInPayable | -4.48M | -3.48M | 4.52M | 1.05M |
| ChangeInAccountPayable | -4.48M | -3.48M | 4.52M | 1.05M |
| ChangeInPrepaidAssets | -2.44M | 1.60M | -7.41M | -7.38M |
| ChangeInReceivables | -15.37M | -1.14M | 56.67M | -47.40M |
| ChangesInAccountReceivables | -15.37M | -1.14M | 56.67M | -47.40M |
| OtherNonCashItems | 51.88M | 24.83M | 57.68M | 32.38M |
| StockBasedCompensation | 97.84M | 72.06M | 47.85M | 26.83M |
| AssetImpairmentCharge | 0.00 | 0.00 | 2.84M | |
| DepreciationAmortizationDepletion | 9.53M | 11.89M | 5.81M | 2.28M |
| DepreciationAndAmortization | 9.53M | 11.89M | 5.81M | 2.28M |
| Depreciation | 9.53M | 11.89M | 5.81M | 2.28M |
| OperatingGainsLosses | -1.27M | 35.00K | 2.80M | |
| GainLossOnInvestmentSecurities | -1.32M | 35.00K | 107.00K | |
| GainLossOnSaleOfPPE | 45.00K | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -589.53M | -526.24M | -388.95M | -215.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CYTK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|